<?xml version="1.0" encoding="UTF-8"?>
<p>These findings highlighted the importance of CDK-2 as a potential target in cancer chemotherapy. Several small molecule inhibitors of CDK-2 have proved potent anticancer activities
 <xref rid="CIT0006" ref-type="bibr">
  <sup>6</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0014" ref-type="bibr">
  <sup>14</sup>
 </xref>. However, many of these inhibitors have also displayed pan-CDKs inhibitory activity which could be attributed to the high sequence similarity between different members of the CDK family
 <xref rid="CIT0006" ref-type="bibr">
  <sup>6</sup>
 </xref>. Some of these inhibitors (roscovitine, dinaciclib, and Ro-3306) have succeeded to reach phase I/II clinical trials
 <xref rid="CIT0006" ref-type="bibr">
  <sup>6</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0014" ref-type="bibr">
  <sup>14</sup>
 </xref>.
</p>
